Apheresis Medicine State of the Art in 2010: American Society for Apheresis Fifth Special Edition of the Journal of Clinical Apheresis

被引:8
|
作者
Winters, Jeffrey L. [1 ]
机构
[1] Mayo Clin, Div Transfus Med, Dept Lab Med & Pathol, Rochester, MN 55905 USA
关键词
guidelines; apheresis; evidence-based medicine; THERAPEUTIC APHERESIS; GUIDELINES;
D O I
10.1002/jca.20307
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The quality of evidence supporting the use of apheresis in the treatment of individual diseases and disorders is often limited. For most diseases and disorders, randomized controlled trials of the use of apheresis have not been performed and for many, due to rarity of the condition, it is unlikely that they will ever be performed. In keeping with its vision, the American Society for Apheresis (ASFA) has created and regularly updated guidelines on the use of apheresis in the treatment of disease. These guidelines seek to summarize the literature on the use of apheresis in treating diseases, provide a critical review of this literature, and give practical guidance to apheresis practitioners. The most recent ASFA guidelines were published in 2010. This article reviews the history of the ASFA guidelines, the changes that were made in the 2010 guidelines, and future directions and plans for these guidelines. The 2010 ASFA guidelines on the use of therapeutic apheresis in clinical practice represent the state of the art in apheresis medicine in 2010. J. Clin. Apheresis 26: 239-242, 2011. (C) 2011 Wiley-Liss, Inc.
引用
收藏
页码:239 / 242
页数:4
相关论文
共 50 条
  • [41] Do we have enough evidence for recommending therapeutic apheresis for natalizumab-related progressive multifocal leukoencephalopathy patients? Comment on "Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for apheresis: The seventh special issue."
    Landi, Doriana
    Centonze, Diego
    Marfia, Girolama Alessandra
    Capra, Ruggero
    Scarpazza, Cristina
    JOURNAL OF CLINICAL APHERESIS, 2018, 33 (03) : 450 - 451
  • [42] American Society for Apheresis, Society of Hemapheresis Specialists and Francis S. Morrison, MD, revisited
    Strauss, Ronald G.
    JOURNAL OF CLINICAL APHERESIS, 2007, 22 (04) : 246 - 248
  • [43] Lipoprotein apheresis State of the art and case report of the longest HELP treatment worldwide
    Tunnemann-Tarr, Adrienn
    Katzmann, Julius Ludwig
    Thiery, Joachim
    Laufs, Ulrich
    HERZ, 2022, 47 (03) : 228 - 235
  • [44] Apropos the 2016 world apheresis association and French society for hemapheresis meeting special issue
    Heshmati, Farhad
    Garraud, Olivier
    TRANSFUSION AND APHERESIS SCIENCE, 2017, 56 (01) : 9 - 9
  • [46] Recommendations for Therapeutic Apheresis by the Section "Preparative and Therapeutic Hemapheresis" of the German Society for Transfusion Medicine and Immunohematology
    Worel, Nina
    Mansouri Taleghani, Behrouz
    Strasser, Erwin
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2019, 46 (06) : 394 - 406
  • [48] Considerations for immune effector cell therapy collections: a white paper from the American Society for Apheresis
    Liu, Hien D.
    Su, Leon
    Winters, Jeffrey L.
    Thibodeaux, Suzanne R.
    Park, Yara A.
    Wu, YanYun
    Schwartz, Joseph
    Zubair, Abba C.
    Schneiderman, Jennifer
    Gupta, Gaurav K.
    Ramakrishnan, Sharanya
    Aqui, Nicole A.
    CYTOTHERAPY, 2022, 24 (09) : 916 - 922
  • [49] Current state of therapeutic apheresis and cellular therapy education for transfusion medicine fellows in the United States
    Pham, Huy P.
    Tran, Minh-Ha
    JOURNAL OF CLINICAL APHERESIS, 2021, 36 (01) : 87 - 93